Purpose: This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-181. The study will consist of 2 parts: ABBV-181 dose escalation and ABBV-181 dose expansion.
Lung Cancer
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Purpose: In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.
Phase IB of Selinexor in Combination With Standard Chemotherapy in Patients With Advanced Malignancies
Purpose: Primary Objective: To establish the safety and tolerability of Selinexor when given in combination with standard chemotherapy regimens.
Secondary Objectives:To determine disease control and progression free survival of Selinexor administered with standard chemotherapy treatments.
Exploratory Objectives:To determine the correlation of translational biomarkers To compare serial assessment of mutation status in biopsies obtained at baseline and progression after clinical response to combination therapy
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Purpose: This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Purpose: To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Purpose: Mithramycin is a new cancer drug. In another study, people with chest cancer took the drug 6 hours a day for 7 straight days. Many of them had liver damage as a side effect. It was discovered that only people with certain genes got this side effect. Researchers want to test mithramycin in people who do not have those certain genes.
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
Purpose: The aim of this study is to learn about how mesothelioma affects patients’ emotional and physical well-being. Also, the investigators would like to learn more about what patients need and how they deal with this illness. This information can help us find ways to lessen physical and emotional strains. Part of the study tests an alternate way of giving emotional support through the Internet. By providing support online, patients can participate in the comfort of their home.
Mithramycin for Lung, Esophagus, and Other Chest Cancers
Purpose: Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment. Research suggests that it may be useful against some cancers of the chest, such as lung and esophageal cancer or mesothelioma. Researchers want to see if mithramycin can be used to treat these types of cancer.
Objectives
To see if mithramycin is safe and effective against different chest cancers.
Design
Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and tumor tissue samples will be used to monitor the cancer before treatment.
Participants will receive mithramycin every day for 7 days, followed by 7 days without treatment. Each
Treatment will be monitored with frequent blood tests and imaging studies.
Participants will continue to take the drug for as long as the side effects are not severe and the tumor responds to treatment.
Rapid Autopsy and Procurement of Non-Small Cell Lung Cancer Tissue
Purpose: People with lung cancers unfortunately commonly succumb to their disease. Some agree to donate their bodies to cancer research that may help the medical community better understand these diseases. Studies of lung cancer tumor tissue obtained soon after death may be used to answer questions about the origins, progression, and treatment of lung cancer. Researchers want to conduct a study that involves planned collection of lung cancer tumor tissue shortly after death. To do so, they will arrange to provide inpatient hospice care for people with non-small cell lung cancer.
Staging Procedures to Diagnose Malignant Pleural Mesothelioma
Purpose: The purpose of this study is to evaluate the accuracy of participants imaging versus staging procedures. The investigators will consent subjects that are scheduled to undergo staging procedures to diagnose malignant pleural mesothelioma (including pleuroscopy, bronchoscopy, endobronchial ultrasound and laparoscopy) as part of their standard of care.
